Spots Global Cancer Trial Database for urogenital neoplasms
Every month we try and update this database with for urogenital neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | NCT00672009 | Prostatic Disea... Genital Neoplas... Urogenital Neop... Genital Disease... Adenocarcinoma Prostatic Neopl... Neoplasms, Glan... Carcinoma | Ixabepilone | - | Cedars-Sinai Medical Center | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Trial of NanoPac Focal Therapy for Prostate Cancer | NCT04221828 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostatic Neopl... Urogenital Neop... Genital Neoplas... Localized Cance... | NanoPac (steril... | 18 Years - | NanOlogy, LLC | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| Protection of Rectum From High Radiation Doses Using a Spacer | NCT01918605 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | Diluted spacer Non-diluted spa... | 50 Years - 78 Years | University of Oulu | |
| SUTENT® In The First Line Treatment Of Renal Cell Carcinoma | NCT00460798 | Renal Cell Carc... | Sutent: observa... | - | Pfizer | |
| Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients | NCT02444195 | Uterine Cervica... Uterine Neoplas... Ovarian Neoplas... Urogenital Neop... Fallopian Tube ... | Guided Imagery ... | 18 Years - | University of Michigan | |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Potential Therapeutic Response In Urogenital Tumors | NCT03551457 | Urogenital Neop... Drug Therapy | Biopsy | 18 Years - | University of Campinas, Brazil | |
| Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | NCT04679675 | Uterine Cervica... Uterine Neoplas... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Uterine Cervica... Uterine Disease... Cervical Cancer Cervical Dyspla... Human Papilloma... HPV-Related Cer... HPV Infection HPV-Related Mal... | Usual Care Education Direct Mail Opt-in | 30 Years - 64 Years | Kaiser Permanente | |
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment | NCT04435964 | Melanoma Lung Cancer Head and Neck C... Urogenital Neop... Breast Cancer | Immunotherapy | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | NCT04461509 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Genital Disease... Prostatic Disea... | 18F-PSMA | 18 Years - | Cedars-Sinai Medical Center | |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | NCT05030077 | Urothelial Carc... Anlotinib Urogenital Neop... Cisplatin Carboplatin Gemcitabine Antineoplastic ... | Anlotinib Cisplatin Carboplatin Gemcitabine | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy | NCT05887245 | Renal Cell Carc... Kidney Neoplasm Urologic Neopla... Urogenital Neop... Kidney Diseases | 18 Years - | Centre of Postgraduate Medical Education | ||
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients | NCT01523652 | Genital Disease... Ovarian Neoplas... Urogenital Neop... | 18 Years - | Azienda Ospedaliera San Giovanni Battista | ||
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Potential Therapeutic Response In Urogenital Tumors | NCT03551457 | Urogenital Neop... Drug Therapy | Biopsy | 18 Years - | University of Campinas, Brazil | |
| Expanded Access to NanoDoce | NCT04060628 | Urogenital Neop... | NanoDoce (steri... | - | NanOlogy, LLC | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | NCT04597411 | Prostatic Neopl... | 225^Ac-PSMA-617 68^Ga-PSMA-11 | 18 Years - | Endocyte | |
| Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery | NCT02847832 | Patients With A... | Standardized tr... | - | KU Leuven | |
| A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | NCT02578797 | Castration-Resi... | Apalutamide | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients | NCT02444195 | Uterine Cervica... Uterine Neoplas... Ovarian Neoplas... Urogenital Neop... Fallopian Tube ... | Guided Imagery ... | 18 Years - | University of Michigan | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | NCT01316458 | Prostatic Neopl... Genital Neoplas... Neoplasms, Abdo... Urogenital Neop... Genital Disease... Prostatic Disea... Antineoplastic ... Imatinib | STI571 (Glivec®... | 18 Years - | Novartis | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | NCT05592626 | Advanced Solid ... Genital Neoplas... Urogenital Neop... Lung Neoplasm Neoplasms by Si... Papillomavirus ... Epstein-Barr Vi... Carcinoma Neoplasms Vulvar Neoplasm... Vulvar Diseases Abdominal Neopl... | STAR0602 | 18 Years - | Marengo Therapeutics, Inc. | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | NCT00749502 | Solid Tumors Chronic Lymphoc... T-cell-prolymph... | MK-4827 | 18 Years - | Tesaro, Inc. | |
| Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab | NCT06237920 | Urologic Neopla... Urogenital Neop... Neoplasms by Si... Neoplasms Female Urogenit... Female Urogenit... Urogenital Dise... Urinary Bladder... Male Urogenital... Urinary Bladder... Antineoplastics... | Nivolumab Relatlimab | 18 Years - | The Netherlands Cancer Institute | |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | NCT02266745 | Advanced Solid ... CRPC mCRPC Metastatic Cast... PT-112 Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | PT-112 Injectio... | 18 Years - | Promontory Therapeutics Inc. | |
| Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | NCT03562897 | Carcinoma Ovarian Neoplas... Endocrine Gland... Urogenital Neop... Ovarian Disease... Adnexal Disease... Genital Disease... Female Urogenit... Female Urogenit... Endocrine Syste... Gonadal Disorde... Genital Neoplas... Neoplasms, Glan... | Ocoxin-Viusid | 18 Years - | Catalysis SL | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | NCT03933826 | Bladder Cancer Cancer of the B... Non-muscle Inva... | 18 Years - | University of Washington | ||
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | NCT05067140 | Prostate Cancer... | ARV-766 Part A&... ARV-766 + Abira... | 18 Years - | Arvinas Inc. | |
| A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer | NCT01654458 | Sexual Dysfunct... Uterine Cervica... Ovarian Neoplas... Uterine Neoplas... Genital Neoplas... | GyneGals Suppor... | 18 Years - | Women's College Hospital | |
| Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | NCT04519151 | Ovarian Neoplas... Carcinoma, Ovar... Neoplasm of Sto... Ovarian Disease... Genital Neoplas... Ovarian Epithel... Urogenital Neop... Neoplasms, Glan... | Pembrolizumab Lenvatinib | 18 Years - | Sheba Medical Center | |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) | NCT04922047 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Antineoplastic ... Urinary Bladder... Tislelizumab An... | tislelizumab an... | 18 Years - 75 Years | RenJi Hospital | |
| A Trial for Patients With Advanced/Recurrent Endometrial Cancer | NCT00377520 | Neoplasms Neoplasms by Si... Urogenital Neop... Genital Neoplas... Uterine Neoplas... Endometrial Neo... Cancer of Endom... Endometrial Can... Cancer of the E... Endometrium Can... Neoplasms, Endo... | pemetrexed | - | Eli Lilly and Company | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Health Gatherings - For Your Health After Cancer | NCT03344757 | Prostate Neopla... Genital Neoplas... Urogenital Neop... Neoplasm, Prost... Genital Disease... Prostatic Disea... | Cultural CBSM Standard CBSM | 18 Years - | University of Miami | |
| Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma | NCT04644432 | Metastatic Rena... Kidney Neoplasm Urologic Neopla... Urogenital Neop... | Medication (A s... Patient reporte... | 18 Years - | Herlev and Gentofte Hospital | |
| SUTENT® In The First Line Treatment Of Renal Cell Carcinoma | NCT00460798 | Renal Cell Carc... | Sutent: observa... | - | Pfizer | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | NCT03636256 | Bladder Cancer Urothelial Carc... Urinary Bladder... Urinary Bladder... Urogenital Neop... Urologic Neopla... Urologic Cancer Malignant Tumor... Cancer of the B... | NanoDoce (direc... NanoDoce (intra... Institutional S... NanoDoce (intra... | 18 Years - | NanOlogy, LLC | |
| Alkagin Paste in the Prevention of Radiation Dermatitis | NCT01408407 | Anus Neoplasms Rectal Neoplasm... Urogenital Neop... | Aveeno cream Alkagin paste | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391 | Prostatic Neopl... Prostate Cancer Prostatic Adeno... | sipuleucel-T leuprolide acet... | 18 Years - | Dendreon | |
| Acupuncture for the Immune System in Radiation Cancer Patients | NCT01422928 | Gastrointestina... Urogenital Neop... | Medical Acupunc... | - | British Columbia Cancer Agency | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | NCT01217697 | Prostate Neopla... Genital Neoplas... Urogenital Neop... Genital Disease... | Abiraterone Ace... Prednisone\Pred... | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | NCT01316458 | Prostatic Neopl... Genital Neoplas... Neoplasms, Abdo... Urogenital Neop... Genital Disease... Prostatic Disea... Antineoplastic ... Imatinib | STI571 (Glivec®... | 18 Years - | Novartis | |
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | NCT04679675 | Uterine Cervica... Uterine Neoplas... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Uterine Cervica... Uterine Disease... Cervical Cancer Cervical Dyspla... Human Papilloma... HPV-Related Cer... HPV Infection HPV-Related Mal... | Usual Care Education Direct Mail Opt-in | 30 Years - 64 Years | Kaiser Permanente | |
| CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | NCT04811846 | Urinary Bladder... Transitional Ce... Urogenital Neop... Circulating Tum... Neoplasms | Bipolar transur... Bipolar transur... | 18 Years - | University Teaching Hospital Hall in Tirol | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma | NCT01441661 | Renal Cell Carc... | - | Cancer Foundation, China | ||
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | NCT00753415 | Non-Small Cell ... Breast Cancer Melanoma Upper GI Tract ... Colon Carcinoma Renal Cell Carc... Bladder Carcino... Prostate Cancer | V935 V934-EP | 18 Years - | Merck Sharp & Dohme LLC | |
| Acupuncture for the Immune System in Radiation Cancer Patients | NCT01422928 | Gastrointestina... Urogenital Neop... | Medical Acupunc... | - | British Columbia Cancer Agency | |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | NCT05067140 | Prostate Cancer... | ARV-766 Part A&... ARV-766 + Abira... | 18 Years - | Arvinas Inc. | |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | NCT02543645 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms by Hi... Neoplasms Clear-cell Meta... Melanoma Triple Negative... Bladder Cancer Head and Neck C... Non-small Cell ... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | NCT02049190 | Prostate Cancer Metastatic Pros... Androgen-indepe... Recurrent Prost... | onapristone abiraterone | 18 Years - | Arno Therapeutics | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | NCT04679675 | Uterine Cervica... Uterine Neoplas... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Uterine Cervica... Uterine Disease... Cervical Cancer Cervical Dyspla... Human Papilloma... HPV-Related Cer... HPV Infection HPV-Related Mal... | Usual Care Education Direct Mail Opt-in | 30 Years - 64 Years | Kaiser Permanente | |
| A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer | NCT01654458 | Sexual Dysfunct... Uterine Cervica... Ovarian Neoplas... Uterine Neoplas... Genital Neoplas... | GyneGals Suppor... | 18 Years - | Women's College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
